B+
Bull case
20%
Probability
Target price
$5.00
Analysis reference price unavailable
Analysis 2026-10-14 · RankAlpha Sentiment Codex
NERV
Minerva NeurosciencesCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
A successful Phase A efficacy result could substantially improve roluperidone's development prospects. Minerva says the confirmatory C19 study remains on track for a second-half 2027 topline readout.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
A failed or delayed C19 Phase A readout would directly challenge the central investment thesis. [#SEC-8K-2026-08-07]
Momentum
86
Value
41
Sentiment
58
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.40 · Bull $5.00 · Bear $0.80Analysis 2026-10-14; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $10.33
Why
Momentum86 · Δ7d -
Value41 · Δ7d -0.1
Sentiment58 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • A failed or delayed C19 Phase A readout would directly challenge the central investment thesis. [#SEC-8K-2026-08-07]
- • Non-cash warrant revaluation makes GAAP earnings volatile and can obscure operating losses; preferred stock, warrants and the future-royalty liability complicate equity valuation. [#SEC-8K-2026-08-07]
- • The thesis is concentrated in one late-stage program.
Catalyst clock
2026-12-31
C19 spending and financing risk
Lead driver: Sentiment · See AI snapshot
Momentum
86
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
58
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 85.6 / Value 40.6 / Sentiment 58.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-14. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$2.40
Analysis reference price unavailable
Analysis 2026-10-14 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.80
Analysis reference price unavailable
Analysis 2026-10-14 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$109.82M
Beta
-0.24
Shares Out
47.75M
P/E (TTM)
2.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.13
Rev YoY
-100.0%
EPS YoY
-68.0%
Gross Margin
-
Op Margin
-
Net Debt
-$17.44M
Current Ratio
20.14
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data